1. Home
  2. LQDA

LQDA

Liquidia Corporation

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Founded: 2004 Country:
United States
United States
Employees: N/A City: MORRISVILLE
Market Cap: 1.2B IPO Year: 2018
Target Price: $21.60 AVG Volume (30 days): 925.8K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.21 EPS Growth: N/A
52 Week Low/High: $5.71 - $16.99 Next Earning Date: 05-02-2024
Revenue: $17,488,000 Revenue Growth: 9.75%
Revenue Growth (this year): 225.57% Revenue Growth (next year): 202.31%

Share on Social Networks: